Patents by Inventor Willem J.M. Mulder

Willem J.M. Mulder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11859021
    Abstract: Provided herein are compounds of Formula (I), as well as compositions comprising a compound of Formula (I) and uses thereof.
    Type: Grant
    Filed: March 18, 2022
    Date of Patent: January 2, 2024
    Assignees: Icahn School of Medicine at Mount Sinai, Trained Therapeutix Discovery, Inc.
    Inventors: Henricus Marie Janssen, Freek Johannes Maria Hoeben, Bas Van Genabeek, Serge Hendrikus Mathijs Sontjens, Willem J. M. Mulder
  • Publication number: 20220332762
    Abstract: Provided herein are compounds of Formula (I), as well as compositions comprising a compound of Formula (I) and uses thereof.
    Type: Application
    Filed: March 18, 2022
    Publication date: October 20, 2022
    Inventors: Henricus Marie JANSSEN, Freek Johannes Maria HOEBEN, Bas VAN GENABEEK, Serge Hendrikus Mathijs SONTJENS, Willem J. M. MULDER
  • Publication number: 20150343100
    Abstract: Described herein is a non-invasive quantitative positron emission tomography (PET) nanoreporter technology that allows personalized therapeutic outcome prediction. In a breast cancer mouse model, it was demonstrated that co-injecting Doxil and a Zirconium-89 nanoreporter (89Zr-NRep) enabled highly precise doxorubicin (DOX) quantification. Imaging 89Zr-NRep via PET revealed remarkable Doxil accumulation heterogeneity independent of tumor size.
    Type: Application
    Filed: May 27, 2015
    Publication date: December 3, 2015
    Inventors: Carlos Perez-Medina, Thomas Reiner, Jason S. Lewis, Willem J.M. Mulder, Zahi A. Fayad